Durable Responses from Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study

被引：2

作者：

Davies, Andrew J. ^{[1
,2
]}

Caddy, Josh ^{[3
]}

McLaughlin, Katy ^{[3
]}

Wignall, Christopher ^{[3
]}

Waugh, Robert ^{[3
]}

Collins, Graham P. ^{[4
]}

Stanton, Louise ^{[3
]}

Saunders, Geoff N. ^{[3
]}

Cummin, Thomas ^{[5
]}

Schuh, Anna ^{[6
]}

Ardeshna, Kirit M. ^{[7
]}

McMillan, Andrew K. ^{[8
]}

Radford, John ^{[9
,10
]}

Lewis, David John ^{[11
]}

Coleman, Adam R. ^{[1
]}

Griffiths, Gareth ^{[3
]}

Burton, Cathy ^{[12
]}

Barrans, Sharon ^{[12
]}

Johnson, Peter ^{[1
,13
]}

机构：

[1] Canc Res UK Expt Canc Med Ctr UK, Southampton, Hants, England

[2] Southampton Canc Res UK Ctr, Southampton, Hants, England

[3] Univ Southampton, Canc Res UK Southampton Clin Trials Unit, Southampton, Hants, England

[4] Churchill Hosp, Oxford Canc & Haematol Ctr, Oxford, England

[5] Portsmouth Hosp Univ NHS Trust, Portsmouth, Hants, England

[6] Univ Oxford, Oxford Mol Diagnost Ctr, Oxford, England

[7] Univ Coll London Hosp NHS Fdn Trust, Dept Haematol, London, England

[8] Nottingham Univ Hosp NHS Trust, Nottingham, England

[9] Univ Manchester, NIHR Clin Res Facil, Manchester, Lancs, England

[10] Christie NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England

[11] Derriford Hosp, Dept Haematol, Plymouth, Devon, England

[12] Leeds Canc Ctr, Haematol Malignancy Diagnost Serv, Leeds, W Yorkshire, England

[13] Univ Southampton, Fac Med, Sch Canc Sci, Southampton, Hants, England

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-163499

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：9478 / 9479

页数：2

共 50 条

[31] RANDOMIZED PHASE II STUDY OF R-CHOP PLUS ENZASTAURIN VERSUS R-CHOP IN THE FIRST-LINE TREATMENT OF PATIENTS WITH INTERMEDIATE AND HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) - PRELIMINARY ANALYSIS
Hainsworth, J. D.
Arrowsmith, E. R.
Mccleod, M.
Fayad, L. E.
Hamid, O.
Davis, L.
Lin, B.
ANNALS OF ONCOLOGY, 2011, 22 : 107 - 107
[32] Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study
Kate Manos
Geoffrey Chong
Colm Keane
Sze-Ting Lee
Charmaine Smith
Leonid Churilov
Joseph McKendrick
William Renwick
Piers Blombery
Melinda Burgess
Niles Elizabeth Nelson
Tineke Fancourt
Joanne Hawking
Wendi Lin
Andrew M. Scott
Allison Barraclough
Joel Wight
Andrew Grigg
Chun Yew Fong
Eliza A. Hawkes
Leukemia, 2023, 37 : 1092 - 1102
[33] Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID)
Drott, Kristina
Hagberg, Hans
Papworth, Karin
Relander, Thomas
Jerkeman, Mats
BLOOD ADVANCES, 2018, 2 (12) : 1386 - 1392
[34] Combination of everolimus with R-CHOP (ever R-CHOP) as an initial therapy for diffuse large B-cell lymphoma (DLBCL): A phase I and feasibility study (NCCTG N1085 [Alliance]).
Johnston, Patrick B.
LaPlant, Betsy
Nowakowski, Grzegorz S.
Micallef, Ivana N. M.
Ansell, Stephen Maxted
Habermann, Thomas Matthew
Colgan, Joseph
Witzig, Thomas E.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[35] Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study
Manos, Kate
Chong, Geoffrey
Keane, Colm
Lee, Sze-Ting
Smith, Charmaine
Churilov, Leonid
McKendrick, Joseph
Renwick, William
Blombery, Piers
Burgess, Melinda
Nelson, Niles Elizabeth
Fancourt, Tineke
Hawking, Joanne
Lin, Wendi
Scott, Andrew M.
Barraclough, Allison
Wight, Joel
Grigg, Andrew
Fong, Chun Yew
Hawkes, Eliza A.
LEUKEMIA, 2023, 37 (05) : 1092 - 1102
[36] Clinicopathologic Significance of CD11c, CD16 and FOXP3 Expression in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Receiving Rituximab, Cyclophosphamide, Anthracycline, Vincristine, and Prednisolone (R-CHOP) Combination Chemotherapy
Oh, Sung Yong
Jung, Jin Sook
Kim, Sung Hyun
BLOOD, 2012, 120 (21)
[37] Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study
Tilly, Herve
Morschhauser, Franck
Bartlett, Nancy L.
Sharman, Jeff
Haioun, Corinne
Kolibaba, Kathryn S.
Chen, Andy
Lamy, Thierry
Jones, Surai
Penuel, Elicia
Lee, Calvin
Salles, Gilles A.
BLOOD, 2016, 128 (22)
[38] A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma
Morschhauser, Franck
Feugier, Pierre
Flinn, Ian W.
Gasiorowski, Robin
Greil, Richard
Illes, Arpad
Johnson, Nathalie A.
Larouche, Jean-Francois
Lugtenburg, Pieternella J.
Patti, Caterina
Salles, Gilles Andre
Trneny, Marek
de Vos, Sven
Mir, Farheen
Samineni, Divya
Kim, Su Y.
Jiang, Yanwen
Punnoose, Elizabeth
Sinha, Arijit
Clark, Emma
Spielewoy, Nathalie
Humphrey, Kathryn
Bazeos, Alexandra
Zelenetz, Andrew D.
BLOOD, 2021, 137 (05) : 600 - 609
[39] Efficacy and tolerability of rituximab and reduced-dose cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy for elderly patient with diffuse large B-cell lymphoma
Kayamori, Kensuke
Shono, Katsuhiro
Onoda, Masahiro
Yokota, Akira
HEMATOLOGY, 2019, 24 (01) : 52 - 59
[40] Evaluation of prognostic values of clinical and histopathologic characteristics in diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy
Hong, Junshik
Park, Sanghui
Park, Jinny
Kim, Hyung Sun
Kim, Kyung-Hee
Ahn, Jeong Yeal
Rim, Min Young
Jung, Minkyu
Sym, Sun Jin
Cho, Eun Kyung
Shin, Dong Bok
Lee, Jae Hoon
LEUKEMIA & LYMPHOMA, 2011, 52 (10) : 1904 - 1912

← 1 2 3 4 5 →